Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11980MR)

This product GTTS-WQ11980MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11980MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3736MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ5536MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ5096MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ2945MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ6454MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ7035MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ5654MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ2324MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW